

John W Newcomer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8212152/publications.pdf>

Version: 2024-02-01

160
papers

15,007
citations

25034

57
h-index

18130

120
g-index

167
all docs

167
docs citations

167
times ranked

12597
citing authors

#	ARTICLE	IF	CITATIONS
1	Lessons Learned From a New Reverse-Integration Model to Improve Primary Care Screening in Community Mental Health Settings. <i>Psychiatric Services</i> , 2022, 73, 942-945.	2.0	7
2	Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers. <i>Neuropsychopharmacology</i> , 2022, 47, 696-703.	5.4	6
3	Lurasidone and risk for metabolic syndrome: results from short- and long-term clinical studies in patients with schizophrenia. <i>CNS Spectrums</i> , 2021, 26, 614-624.	1.2	7
4	Smoking cessation treatment for individuals with comorbid diabetes and serious mental illness in an integrated health care delivery system. <i>Addictive Behaviors</i> , 2021, 114, 106697.	3.0	3
5	PANSS Individual Item and Marder Dimension Analyses From a Pivotal Trial of RBP-7000 (Monthly) Tj ETQq1 1 0.784314 rgBT ₂ /Overlo	2.2	2
6	Reanalysis of a Phase 3 Trial of a Monthly Extended-Release Risperidone Injection for the Treatment of Acute Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 76-77.	1.4	1
7	Comorbid Diabetes and Severe Mental Illness: Outcomes in an Integrated Health Care Delivery System. <i>Journal of General Internal Medicine</i> , 2020, 35, 160-166.	2.6	10
8	Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia. <i>Comprehensive Psychiatry</i> , 2020, 102, 152195.	3.1	5
9	Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study. <i>American Journal of Psychiatry</i> , 2020, 177, 1168-1178.	7.2	72
10	The Eleventh Judicial Circuit Criminal Mental Health Project: Improving Access to Mental Health Treatment in Miami-Dade County. <i>Psychiatric Services</i> , 2020, 71, 1091-1094.	2.0	1
11	Depression and Nicotine Withdrawal Associations with Combustible and Electronic Cigarette Use. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9334.	2.6	4
12	184 Insulin Sensitivity and Glucose Metabolism of Olanzapine and Combination Olanzapine and Samidorphan: A Phase 1 Exploratory Study in Healthy Volunteers. <i>CNS Spectrums</i> , 2020, 25, 316-316.	1.2	2
13	160 Lurasidone and Metabolic Syndrome: Results from Short- and Long-Term Clinical Studies in Patients with Bipolar Depression. <i>CNS Spectrums</i> , 2020, 25, 302-303.	1.2	5
14	Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	86
15	F27. EFFICACY OF MONTHLY EXTENDED-RELEASE RISPERIDONE INJECTIONS (RBP-7000) FOR THE TREATMENT OF SCHIZOPHRENIA: AN ANALYSIS OF INDIVIDUAL PANSS ITEMS. <i>Schizophrenia Bulletin</i> , 2019, 45, S264-S265.	4.3	0
16	Adiposity, Hepatic Triglyceride, and Carotid Intima Media Thickness During Behavioral Weight Loss Treatment in Antipsychotic-Treated Youth: A Randomized Pilot Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 439-447.	1.3	10
17	Getting to precision psychopharmacology: Combining clinical and genetic information to predict fat gain from aripiprazole. <i>Journal of Psychiatric Research</i> , 2019, 114, 67-74.	3.1	3
18	Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	3

#	ARTICLE	IF	CITATIONS
19	Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 428-433.	1.4	14
20	Diabetes Screening among Antipsychotic-Treated Adults with Severe Mental Illness in an Integrated Delivery System: A Retrospective Cohort Study. <i>Journal of General Internal Medicine</i> , 2018, 33, 79-86.	2.6	17
21	A Doctor is in the House: Stakeholder Focus Groups About Expanded Scope of Practice of Community Psychiatrists. <i>Community Mental Health Journal</i> , 2018, 54, 507-513.	2.0	10
22	Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies. <i>Current Medical Research and Opinion</i> , 2018, 34, 2197-2205.	1.9	14
23	Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis. <i>BMC Health Services Research</i> , 2018, 18, 243.	2.2	6
24	Gestational Diabetes Risk During Treatment With Antipsychotic Medications. <i>American Journal of Psychiatry</i> , 2018, 175, 498-499.	7.2	0
25	Diabetes and Prediabetes Prevalence by Race and Ethnicity Among People With Severe Mental Illness. <i>Diabetes Care</i> , 2018, 41, e119-e120.	8.6	16
26	Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths. <i>JAMA Psychiatry</i> , 2018, 75, 788.	11.0	54
27	Rates of Cervical Cancer Screening Among Women With Severe Mental Illness in the Public Health System. <i>Psychiatric Services</i> , 2017, 68, 839-842.	2.0	21
28	Diabetes Prevalence Among Racial-Ethnic Minority Group Members With Severe Mental Illness Taking Antipsychotics: Double Jeopardy?. <i>Psychiatric Services</i> , 2017, 68, 843-846.	2.0	12
29	First-Episode Schizophrenia and Diabetes Risk. <i>JAMA Psychiatry</i> , 2017, 74, 761.	11.0	1
30	Simulated Effects of Policies to Reduce Diabetes Risk Among Adults With Schizophrenia Receiving Antipsychotics. <i>Psychiatric Services</i> , 2017, 68, 1280-1287.	2.0	3
31	Understanding the Cost of a New Integrated Care Model to Serve CMHC Patients Who Have Serious Mental Illness. <i>Psychiatric Services</i> , 2017, 68, 990-993.	2.0	8
32	Nonpsychiatric Outpatient Care for Adults With Serious Mental Illness in California: Who Is Being Left Behind?. <i>Psychiatric Services</i> , 2017, 68, 689-695.	2.0	12
33	Utilization of the Behavior Change Wheel framework to develop a model to improve cardiometabolic screening for people with severe mental illness. <i>Implementation Science</i> , 2017, 12, 134.	6.9	42
34	Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review. <i>Journal of General Internal Medicine</i> , 2016, 31, 1083-1091.	2.6	73
35	Glucose Testing for Adults Receiving Medicaid and Antipsychotics: A Population-Based Prescriber Survey on Behaviors, Attitudes, and Barriers. <i>Psychiatric Services</i> , 2016, 67, 798-802.	2.0	6
36	Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 230-238.	2.6	43

#	ARTICLE	IF	CITATIONS
37	The Role of Clinical Setting and Management Approach in Metabolic Testing Among Youths and Adults Treated With Antipsychotics. <i>Psychiatric Services</i> , 2016, 67, 128-132.	2.0	10
38	Behavioral Weight Loss Treatment for Youth Treated With Antipsychotic Medications. <i>Scandinavian Journal of Child and Adolescent Psychiatry and Psychology</i> , 2016, 4, 96-104.	0.6	11
39	Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 1519-1525.	2.2	30
40	Diabetes Screening Among Underserved Adults With Severe Mental Illness Who Take Antipsychotic Medications. <i>JAMA Internal Medicine</i> , 2015, 175, 1977.	5.1	29
41	Adiposity and Cardiometabolic Risk in Children With and Without Antipsychotic Drug Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3418-3426.	3.6	2
42	Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2015, 386, 2404-2412.	13.7	229
43	Association of Anxiety Disorders and Depression With Incident Heart Failure. <i>Psychosomatic Medicine</i> , 2014, 76, 128-136.	2.0	61
44	Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone. <i>International Journal of Geriatric Psychiatry</i> , 2014, 29, 962-969.	2.7	16
45	Treatment of diabetes mellitus: the urgent need for multifactorial interventions. <i>American Journal of Managed Care</i> , 2014, 20, 357-9.	1.1	4
46	Implementation of a Weight Loss Program for Latino Outpatients with Severe Mental Illness. <i>Community Mental Health Journal</i> , 2013, 49, 150-156.	2.0	8
47	Lower A1c Targets in Type 2 Diabetes and Increased Mortality: Causal or Casual?. <i>American Journal of Medicine</i> , 2013, 126, 1033-1034.	1.5	4
48	Switching Antipsychotic Medications to Reduce Adverse Event Burden in Schizophrenia: Establishing Evidence-Based Practice. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 1108-1120.	2.2	39
49	Cognitive deficits, obesity and disability in schizophrenia. <i>Translational Neuroscience</i> , 2012, 3, .	1.4	8
50	Exercise improves physical capacity in obese patients with schizophrenia: Pilot study. <i>Schizophrenia Research</i> , 2012, 141, 284-285.	2.0	17
51	Neural Correlates of Weight Gain With Olanzapine. <i>Archives of General Psychiatry</i> , 2012, 69, 1226.	12.3	42
52	Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. <i>Frontiers in Psychiatry</i> , 2012, 3, 62.	2.6	25
53	Treatment-related alteration of cortisol predicts change in neuropsychological function during acute treatment of late-life anxiety disorder. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 454-462.	2.7	23
54	Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 974-980.	2.7	49

#	ARTICLE	IF	CITATIONS
55	Changes in Weight, Plasma Lipids, and Glucose in Adults Treated With Ziprasidone. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e742-e748.	2.2	15
56	The general health of people with schizophrenia. , 2012, , 91-106.		0
57	The general health of people with schizophrenia. , 2012, , 91-106.		0
58	Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. <i>World Psychiatry</i> , 2011, 10, 138-151.	10.4	631
59	Antidepressant Drug Compliance: Reduced Risk of MI and Mortality in Depressed Patients. <i>American Journal of Medicine</i> , 2011, 124, 318-324.	1.5	59
60	Implementation of a Glucose Screening Program Based on Diffusion of Innovation Theory Methods. <i>Psychiatric Services</i> , 2011, 62, 12-14.	2.0	10
61	Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?. <i>BMC Psychiatry</i> , 2011, 11, 197.	2.6	41
62	Small area variation and geographic and patient-specific determinants of metabolic testing in antipsychotic users. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 66-75.	1.9	23
63	Authors' response: How can we produce relevant information for decision makers from small area variation studies?. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 782-783.	1.9	0
64	Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. <i>World Psychiatry</i> , 2011, 10, 52-77.	10.4	1,767
65	A Post Hoc Analysis of Negative Symptoms and Psychosocial Function in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 425-430.	1.4	25
66	Letter. <i>Psychiatric Services</i> , 2010, 61, 1162-1163.	2.0	4
67	Risks From Antipsychotic Medications in Children and Adolescents. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 729.	7.4	1
68	Metabolic Testing Rates in 3 State Medicaid Programs After FDA Warnings and ADA/APA Recommendations for Second-Generation Antipsychotic Drugs. <i>Archives of General Psychiatry</i> , 2010, 67, 17.	12.3	188
69	Metabolic Screening in Children Receiving Antipsychotic Drug Treatment. <i>JAMA Pediatrics</i> , 2010, 164, 344-51.	3.0	136
70	Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. <i>Medical Journal of Australia</i> , 2009, 190, S39-42.	1.7	100
71	Metabolic Screening After the American Diabetes Association's Consensus Statement on Antipsychotic Drugs and Diabetes. <i>Diabetes Care</i> , 2009, 32, 1037-1042.	8.6	160
72	Prevalence and Predictors of Lipid and Glucose Monitoring in Commercially Insured Patients Treated With Second-Generation Antipsychotic Agents. <i>American Journal of Psychiatry</i> , 2009, 166, 345-353.	7.2	166

#	ARTICLE	IF	CITATIONS
73	The incidence of diabetes in atypical antipsychotic users differs according to agent—results from a multisite epidemiologic study. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 791-799.	1.9	98
74	Metabolic Risk Status and Second-Generation Antipsychotic Drug Selection. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 26-32.	1.4	33
75	A 24-Week, Multicenter, Open-Label, Randomized Study to Compare Changes in Glucose Metabolism in Patients With Schizophrenia Receiving Treatment With Olanzapine, Quetiapine, or Risperidone. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 487-499.	2.2	49
76	Comparing the Safety and Efficacy of Atypical Antipsychotics in Psychiatric Patients With Comorbid Medical Illnesses. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 30-36.	2.2	41
77	Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. <i>Schizophrenia Research</i> , 2008, 106, 300-307.	2.0	22
78	Review: Children and adolescents with schizophrenia spectrum disorders respond to antipsychotics, but are susceptible to adverse events. <i>Evidence-Based Mental Health</i> , 2008, 11, 81-81.	4.5	3
79	Long-Term Changes in Weight and Plasma Lipids during Maintenance Treatment with Ziprasidone. <i>Neuropsychopharmacology</i> , 2008, 33, 985-994.	5.4	68
80	A Multicenter, Randomized, Double-Blind Study of the Effects of Aripiprazole in Overweight Subjects With Schizophrenia or Schizoaffective Disorder Switched From Olanzapine. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1046-1056.	2.2	109
81	Addressing cardiometabolic risk during treatment with antipsychotic medications. <i>Current Opinion in Psychiatry</i> , 2008, 21, 613-618.	6.3	31
82	Introduction: Cardiovascular Disease and Metabolic Risk Factors in Patients with Mental Illness. <i>CNS Spectrums</i> , 2008, 13, 3-4.	1.2	4
83	Conclusion: Summary and Recommendations. <i>CNS Spectrums</i> , 2008, 13, 13-14.	1.2	6
84	Prevalence of Baseline Serum Glucose and Lipid Testing in Users of Second-Generation Antipsychotic Drugs. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 316-322.	2.2	96
85	Introduction: cardiovascular disease and metabolic risk factors in patients with mental illness. <i>CNS Spectrums</i> , 2008, 13, 1-14.	1.2	1
86	Elevating the standard of care in the management of cardiometabolic risk factors in patients with mental illness. Conclusion: summary and recommendations. <i>CNS Spectrums</i> , 2008, 13, 13-4.	1.2	1
87	Adiposity and Insulin Sensitivity Derived from Intravenous Glucose Tolerance Tests in Antipsychotic-Treated Patients. <i>Neuropsychopharmacology</i> , 2007, 32, 2561-2569.	5.4	46
88	Severe Mental Illness and Risk of Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 1794.	7.4	355
89	Antipsychotic Medication—Induced Weight Gain and Risk for Diabetes and Cardiovascular Disease. , 2007, , 223-245.		1
90	Comparing Safety and Tolerability of Antipsychotic Treatment. <i>Journal of Clinical Psychiatry</i> , 2007, 68, e07.	2.2	16

#	ARTICLE	IF	CITATIONS
91	Challenges and Solutions to Integrating Mental and Physical Health Care. <i>Journal of Clinical Psychiatry</i> , 2007, 68, e09.	2.2	73
92	Series Introduction and Cardiovascular Disease in Patients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2007, 68, e12.	2.2	59
93	Identifying Metabolic Risks With Antipsychotics and Monitoring and Management Strategies. <i>Journal of Clinical Psychiatry</i> , 2007, 68, e17.	2.2	70
94	Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. <i>Journal of Clinical Psychiatry</i> , 2007, 68 Suppl 1, 20-7.	2.2	97
95	Evidence of switching antipsychotic therapy to improve metabolic disturbances. <i>Journal of Clinical Psychiatry</i> , 2007, 68, e13.	2.2	0
96	Antipsychotic medications: metabolic and cardiovascular risk. <i>Journal of Clinical Psychiatry</i> , 2007, 68 Suppl 4, 8-13.	2.2	122
97	Metabolic syndrome and mental illness. <i>American Journal of Managed Care</i> , 2007, 13, S170-7.	1.1	129
98	The Metabolic Effects of Antipsychotic Medications. <i>Canadian Journal of Psychiatry</i> , 2006, 51, 480-491.	1.9	242
99	Medical Risk in Patients With Bipolar Disorder and Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2006, 67, e16.	2.2	156
100	Medical risk in patients with bipolar disorder and schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2006, 67 Suppl 9, 25-30; discussion 36-42.	2.2	28
101	Medical risk in patients with bipolar disorder and schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2006, 67, e16.	2.2	25
102	Metabolic and Endocrine Disturbances in Psychiatric Disorders: A Multidisciplinary Approach to Appropriate Atypical Antipsychotic Utilization. <i>CNS Spectrums</i> , 2005, 10, 1-16.	1.2	9
103	Clinical Considerations in Selecting and Using Atypical Antipsychotics. <i>CNS Spectrums</i> , 2005, 10, 12-19.	1.2	5
104	Metabolic and Endocrine Disturbances in Psychiatric Disorders: A Multidisciplinary Approach to Appropriate Atypical Antipsychotic Utilization. <i>CNS Spectrums</i> , 2005, 10, 819a-819l.	1.2	1
105	Reply: Plasma Leptin and Antipsychotic-Induced Body Weight Gain. <i>Neuropsychopharmacology</i> , 2005, 30, 1770-1771.	5.4	3
106	Plasma Leptin and Adiposity During Antipsychotic Treatment of Schizophrenia. <i>Neuropsychopharmacology</i> , 2005, 30, 184-191.	5.4	68
107	Arterial Stiffness and Stroke in Hypertension. <i>CNS Drugs</i> , 2005, 19, 1-11.	5.9	559
108	Second-Generation (Atypical) Antipsychotics and Metabolic Effects. <i>CNS Drugs</i> , 2005, 19, 1???93.	5.9	921

#	ARTICLE	IF	CITATIONS
109	Effects of glucocorticoids on declarative memory function in major depression. <i>Biological Psychiatry</i> , 2004, 55, 811-815.	1.3	72
110	Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients. <i>Schizophrenia Research</i> , 2004, 71, 137-144.	2.0	20
111	Metabolic risk during antipsychotic treatment. <i>Clinical Therapeutics</i> , 2004, 26, 1936-1946.	2.5	103
112	Effects of dexamethasone on declarative memory function in posttraumatic stress disorder. <i>Psychiatry Research</i> , 2004, 129, 1-10.	3.3	44
113	The Atypical Antipsychotic Therapy and Metabolic Issues National Survey. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, S1-S6.	1.4	117
114	Atypical Antipsychotics and Metabolic Dysregulation. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, S7-S14.	1.4	110
115	Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2004, 65 Suppl 7, 4-18; quiz 19-20.	2.2	58
116	Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. <i>Journal of Clinical Psychiatry</i> , 2004, 65 Suppl 18, 36-46.	2.2	27
117	Insulin dose response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. <i>Psychoneuroendocrinology</i> , 2003, 28, 809-822.	2.7	233
118	Managing Psychosis in Long-Term Care: Treating the Whole Patient. <i>Journal of the American Medical Directors Association</i> , 2003, 4, H2-H7.	2.5	0
119	Managing Psychosis in Long-Term Care: Treating the Whole Patient. <i>Journal of the American Medical Directors Association</i> , 2003, 4, H2-H7.	2.5	0
120	Abnormalities in Glucose Regulation During Antipsychotic Treatment of Schizophrenia. <i>Archives of General Psychiatry</i> , 2002, 59, 337.	12.3	486
121	Does cognitive function improve with quetiapine in comparison to haloperidol?. <i>Schizophrenia Research</i> , 2002, 53, 239-248.	2.0	172
122	Abnormalities in glucose regulation associated with mental illness and treatment. <i>Journal of Psychosomatic Research</i> , 2002, 53, 925-933.	2.6	56
123	Risperidone-Associated Diabetic Ketoacidosis. <i>Psychosomatics</i> , 2001, 42, 279-280.	2.5	30
124	Glucocorticoid effects on memory function over the human life span. <i>Development and Psychopathology</i> , 2001, 13, 491-513.	2.3	90
125	NMDA receptor regulation of memory and behavior in humans. <i>Hippocampus</i> , 2001, 11, 529-542.	1.9	221
126	Cognitive Neuroendocrinology. <i>Critical Issues in Neuropsychology</i> , 2001, , 5-24.	0.4	0

#	ARTICLE	IF	CITATIONS
127	Glutamatergic transmission. Pharmaceutical Science Series, 2001, , 385-406.	0.0	0
128	Increased Neocortical Neurofibrillary Tangle Density in Subjects With Alzheimer Disease and Psychosis. Archives of General Psychiatry, 2000, 57, 1165.	12.3	147
129	NMDA receptor function, memory, and brain aging. Dialogues in Clinical Neuroscience, 2000, 2, 219-232.	3.7	157
130	Glycine Agonists. Archives of General Psychiatry, 1999, 56, 13.	12.3	59
131	Glucose-Induced Increase in Memory Performance in Patients With Schizophrenia. Schizophrenia Bulletin, 1999, 25, 321-335.	4.3	78
132	Enhancement of Memory in Alzheimer Disease With Insulin and Somatostatin, but Not Glucose. Archives of General Psychiatry, 1999, 56, 1135.	12.3	287
133	NMDA receptor hypofunction model of schizophrenia. Journal of Psychiatric Research, 1999, 33, 523-533.	3.1	884
134	Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis. Neuropsychopharmacology, 1999, 20, 106-118.	5.4	525
135	Insulin Metabolism in Alzheimer's Disease Differs According to Apolipoprotein E Genotype and Gender. Neuroendocrinology, 1999, 70, 146-152.	2.5	147
136	Age- and dose-dependent glucose-induced increases in memory and attention in schizophrenia. Psychiatry Research, 1999, 88, 1-13.	3.3	50
137	Glucocorticoid interactions with memory function in schizophrenia. Psychoneuroendocrinology, 1998, 23, 65-72.	2.7	38
138	Chapter 28 The glutamate synapse in neuropsychiatric disorders: Focus on schizophrenia and Alzheimer's disease. Progress in Brain Research, 1998, 116, 421-437.	1.4	134
139	Dose-Dependent Cortisol-Induced Increases in Plasma Leptin Concentration in Healthy Humans. Archives of General Psychiatry, 1998, 55, 995.	12.3	124
140	Robust Leptin Secretory Responses to Dexamethasone in Obese Subjects*. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3230-3233.	3.6	123
141	Robust Leptin Secretory Responses to Dexamethasone in Obese Subjects. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3230-3233.	3.6	101
142	Memory improvement following induced hyperinsulinemia in alzheimer's disease. Neurobiology of Aging, 1996, 17, 123-130.	3.1	460
143	The effects of chronic corticosterone on memory performance in the platform maze task. Physiology and Behavior, 1996, 59, 1111-1115.	2.1	20
144	Hippocampal MR imaging morphometry by means of general pattern matching.. Radiology, 1996, 199, 787-791.	7.3	89

#	ARTICLE	IF	CITATIONS
145	Platelet serotonin markers and depressive symptomatology. <i>Biological Psychiatry</i> , 1995, 37, 442-447.	1.3	61
146	Commonly Used Therapeutic Doses of Glucocorticoids Impair Explicit Memory. <i>Annals of the New York Academy of Sciences</i> , 1995, 761, 400-402.	3.8	47
147	Glucocorticoid-induced impairment in declarative memory performance in adult humans. <i>Journal of Neuroscience</i> , 1994, 14, 2047-2053.	3.6	417
148	Are There Neurochemical Indicators of Risk for Schizophrenia?. <i>Schizophrenia Bulletin</i> , 1994, 20, 75-88.	4.3	12
149	Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics. <i>Psychopharmacology</i> , 1994, 116, 291-296.	3.1	10
150	Chronic corticosterone treatment impairs spontaneous alternation behavior in rats. <i>Behavioral and Neural Biology</i> , 1994, 61, 186-190.	2.2	53
151	Correlations Between Akathisia and Residual Psychopathology: A By-product of Neuroleptic-Induced Dysphoria. <i>British Journal of Psychiatry</i> , 1994, 164, 834-838.	2.8	26
152	Subcortical dopamine and serotonin turnover during acute and subchronic administration of typical and atypical neuroleptics. <i>Psychopharmacology</i> , 1993, 110, 145-151.	3.1	37
153	Subcortical excitatory amino acid levels after acute and subchronic administration of typical and atypical neuroleptics. <i>European Journal of Pharmacology</i> , 1993, 230, 245-250.	3.5	33
154	Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: A longitudinal study.. <i>Behavioral Neuroscience</i> , 1993, 107, 926-940.	1.2	163
155	Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia. <i>Psychiatry Research</i> , 1992, 41, 191-202.	3.3	20
156	Symptomatology and cognitive impairment associate independently with post-dexamethasone cortisol concentrations in unmedicated schizophrenic patients. <i>Biological Psychiatry</i> , 1991, 29, 855-864.	1.3	61
157	Left-handedness in male schizophrenic patients is associated with increased impairment on the Luria-Nebraska neuropsychological battery. <i>Biological Psychiatry</i> , 1991, 30, 326-334.	1.3	18
158	Distinguishing depression and negative symptoms in unmedicated patients with schizophrenia. <i>Psychiatry Research</i> , 1990, 31, 243-250.	3.3	47
159	Antipsychotic Therapies and Glucose Dysregulation in the Mental Illness Population. , 0, , 657-663.		0
160	Using Innovation-Corps (I-Corps®,) Methods to Adapt a Mobile Health (mHealth) Obesity Treatment for Community Mental Health Settings. <i>Frontiers in Digital Health</i> , 0, 4, .	2.8	4